Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Harbour BioMed (Shanghai) Co., Ltd. currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 5 distinct examiners, reflecting a broad distribution of the company's legal workload. This one-to-one relationship between pending actions and examiners suggests that each application is receiving an independent review from a different individual within the USPTO.
The portfolio's active cases are situated within 3 distinct art units. SYDNEY VAN DRUFF is the busiest examiner for the company, overseeing 1 pending office action. Because there are 5 distinct examiners for 5 pending office actions, each examiner, including SYDNEY VAN DRUFF, is responsible for exactly 1 matter. The involvement of 3 distinct art units indicates that while the technology area is unified, the specific biological or pharmaceutical subject matter is diverse enough to be categorized into different specialized units.
This prosecution profile requires a versatile approach, as the company is dealing with 5 different examiners across 3 art units. Practitioners should be prepared for varying examination styles, even within the same technology area. The lack of examiner concentration means that successful outcomes in one application may not directly influence the others, given the different individuals and art units involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684163 | ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VAN DRUFF, SYDNEY | — |
| 18571174 | BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF | AEDER, SEAN E | — |
| 18287822 | ANTIBODY BINDING CTLA-4 AND USE THEREOF | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002655 | BINDING PROTEIN HAVING H2L2 AND HCAB STRUCTURES | STONEBRAKER, ALYSSA RAE | 32d overdue |
| 18684163 | ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VAN DRUFF, SYDNEY | — |
| 18571174 | BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF | AEDER, SEAN E | — |
| 18287822 | ANTIBODY BINDING CTLA-4 AND USE THEREOF | HOWARD, ZACHARY C | — |
| 18023913 | ROR1-TARGETING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1675 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684163 | ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VAN DRUFF, SYDNEY | — | §102§103§112Other | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18571174 | BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF | AEDER, SEAN E | — | §102§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18287822 | ANTIBODY BINDING CTLA-4 AND USE THEREOF | HOWARD, ZACHARY C | 1674 | §102§103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18023913 | ROR1-TARGETING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18002655 | BINDING PROTEIN HAVING H2L2 AND HCAB STRUCTURES | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Final Rejection | 32d overdue | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial